z-logo
Premium
Interferon‐α‐2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease‐2019
Author(s) -
Yu Jiong,
Lu Xuan,
Tong Ling,
Shi Xiaowei,
Ma Jing,
Lv Feifei,
Wu Jian,
Pan Qiaoling,
Yang Jinfeng,
Cao Hongcui,
Li Lanjuan
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14898
Subject(s) - medicine , hazard ratio , mechanical ventilation , inhalation , confounding , clinical endpoint , confidence interval , intensive care unit , subgroup analysis , gastroenterology , randomized controlled trial , anesthesia
Aims Type 1 interferon (IFN) is used to treat patients with coronavirus disease‐2019 (COVID‐19) but robust supporting evidence is lacking. We investigated the association between IFN‐α‐2b and the clinical outcomes of patients with COVID‐19. Methods A total of 1401 patients were enrolled, with 852 (60.8%) patients receiving 5 000 000 U of IFN‐α‐2b via aerosol inhalation twice daily. The primary outcome was a composite measure consisting of mechanical ventilation, intensive care unit (ICU) admission and death. A subgroup analysis was performed to investigate the impact of the IFN‐α‐2b initiation schedule on symptom onset. Results The risk probability for crude endpoints was lower in the IFN‐α‐2b group (3.8%) than in the non‐IFN‐α‐2b group (9.3%, P  < .001). After adjusting the confounding factors, IFN‐α‐2b therapy achieved a reduction of 64% in occurrence of endpoint events (hazard ratio, 0.36; 95% confidence interval [CI], 0.21–0.62). In the subgroup analysis, compared with patients who received IFN‐α‐2b treatment 0–2 days after symptom onset, the hazard ratio for endpoints was 2.2 (95% CI, 0.43–11.13) in patients who received the therapy 3–5 days after symptom onset, 5.89 (95% CI, 0.99–35.05) in patients who received the therapy 6–8 days after symptom onset, and remained at a high level thereafter. Conclusions IFN‐α‐2b aerosol inhalation therapy may be associated with improved clinical outcomes in patients with COVID‐19, and delayed IFN‐α‐2b intervention was associated with increased probabilities of risk events. Further randomized clinical trials are needed to validate the preliminary findings of this study.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here